Kimberly-Clark Corporation (NASDAQ: KMB) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the ...

Dr. AJ Sumell, economics professor at Youngstown State University, said it's still to be determined just how many jobs other ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

U.S. futures followed global markets higher ahead of another big week of corporate earnings reports but an absence of economic data as the U.S. government shutdown entered its second month ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...

Personal healthcare products provider Kenvue Inc. (NYSE:KVUE) has been in the news for one reason or another recently.

Yacktman Asset Management's Q3 2025 13F portfolio value declined to $7.26B, with 70 holdings and ~9% cash. Learn more about ...

Clark’s stock continued for a second day and raised the prospect that an activist investor could surface and try to block its ...

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...